OTTMUSG00000016823 Inhibitors
Proline-rich protein 33 (PRR33) is involved in various cellular processes, and its inhibition can be approached indirectly by targeting signaling pathways that interact with or regulate its function. The chemicals listed above are potential inhibitors that act on different signaling pathways, which might indirectly influence PRR33 activity or its involvement in cellular processes. LY294002 and Wortmannin, both PI3K inhibitors, can potentially disrupt PRR33's function by modulating the PI3K pathway, which is known to interact with various proline-rich proteins. Similarly, Rapamycin, by inhibiting mTOR in the PI3K/AKT/mTOR pathway, could indirectly affect processes in which PRR33 is involved. PD98059 and U0126, as inhibitors of MEK in the MAPK/ERK pathway, may also indirectly influence PRR33's function, considering the potential interactions between this pathway and proline-rich proteins.
In addition, SB203580 and SP600125, targeting p38 MAPK and JNK respectively in the MAPK pathway, could have indirect implications for PRR33's role in cell signaling. Broad-spectrum tyrosine kinase inhibitors like Dasatinib, Imatinib, and Sorafenib might also impact PRR33 indirectly by modulating kinase activities that are potentially linked to PRR33's function or its regulatory mechanisms. Erlotinib and Gefitinib, both EGFR inhibitors, represent another approach to potentially influence PRR33 indirectly by affecting EGFR signaling pathways that might intersect with proline-rich protein functions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. Since PI3K signaling can modulate various proline-rich proteins, inhibiting this pathway can indirectly inhibit PRR33's function in cells. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor. By inhibiting PI3K, it can potentially disrupt downstream processes that involve PRR33, indirectly inhibiting its function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a key kinase in the PI3K/AKT/mTOR pathway. Since this pathway is crucial for multiple cellular processes, its inhibition can indirectly affect PRR33's role. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. As this pathway can interact with proline-rich protein functions, inhibiting MEK may indirectly inhibit PRR33. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 inhibits p38 MAPK, a kinase involved in the MAPK pathway. This inhibition might indirectly affect the function of PRR33 in cellular signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, key kinases in the MAPK/ERK pathway. By inhibiting MEK1/2, U0126 might indirectly affect PRR33 functions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. Inhibiting JNK, part of the MAPK pathway, might impact the functions or interactions of PRR33. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor. By inhibiting certain tyrosine kinases, it might indirectly impact PRR33's function or interactions. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor, known for inhibiting BCR-ABL. Its inhibition of other kinases might indirectly affect PRR33's function. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a kinase inhibitor that targets several tyrosine protein kinases. This broad inhibition might indirectly affect PRR33's function. | ||||||